Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04000009 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
A Phase 3 study, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
NCT04000009: Clinical Trial Phase 3 study, sponsored by ACADIA Pharmaceuticals.
NCT04000009 is a Phase 3 study that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 235 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04000009, a Phase 3 study, was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
Primary Outcome
Number of patients with treatment emergent AEs
Interventions
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 3 |
Why NCT04000009 stopped before completion
NCT04000009 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin is the first listed.
NCT04000009 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04000009 about?
NCT04000009 is a clinical study titled "Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment". To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
What is the current status of trial NCT04000009?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2019-06-06. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT04000009?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT04000009?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04000009's enrollment target sits among peer trials
235 1296th of 2000 higher than 704 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01524211 · 235 participants · NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- NCT05316155 · 235 participants · Phase 1
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05353569 · 235 participants · NA
Coherent Optical Detection of Middle Ear Disease
- NCT05390918 · 235 participants · NA
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI